Randomized, controlled trial of treatments for second-stage sleeping sickness [5]

Journal of Infectious Diseases

Volumn 196, Issue 4, 2007, Pages 650-657

  Woodrow, Charles Jonathan ^a   Abel, Paulo Manuel ^b   Krishna, Sanjeev ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ANGOTRIP   (Angola)

Author keywords

[No Author keywords available]

Indexed keywords

MELARSOPROL; NIFURTIMOX;

AFRICAN TRYPANOSOMIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; MELARSOPROL; NIFURTIMOX; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 34547637092     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/519745     Document Type: Letter

References (3)

1. Bisser S, N'Siesi F-X, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007; 195:322-9.
2. Pepin J. Combination therapy for sleeping sickness: a wake-up call. J Infect Dis 2007; 195:311-3.
3. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152-60.